3 completed, 1 unknown. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Time: new trials by email Literature Review of Time trials Research Report on Time
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting Gentamicin, Standard of Care - Urinary Tract Infections | Phase 2 | Unknown | Mercy Health Ohio | 160 | 2022-10-01 | 2023-01-27 |
| Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time, Qishen Yiqi dripping pills 4 bags/time, Qishen Yiqi dripping pills placebo 4 bags/time - Chronic Heart Failure With Preserved Ejection Fraction | Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 225 | 2021-10-18 | 2026-10-23 |
| Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan - Esophageal Cancer, Gastric Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2008-08-01 | 2016-02-03 |
| Dietary Treatment of Crohn's Disease Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet - Crohn's Disease, Inflammatory Bowel Disease | Phase 1 / Phase 2 | Completed | Rush University Medical Center | 73 | 2006-09-01 | 2021-06-09 |
Crohn Disease (1) · Esophageal Neoplasms (1) · Inflammatory Bowel Diseases (1) · Stomach Neoplasms (1) · Urinary Tract Infections (1)
Memorial Sloan Kettering Cancer Center (1) · Mercy Health Ohio (1) · Rush University Medical Center (1) · Tasly Pharmaceutical Group Co., Ltd (1)
United States (3) · China (1)
Ali Keshavarzian, MD (1) · David Ilson, MD,PhD (1) · Ece A Mutlu, MD MBA (1) · Shahriar Sedghi, MD (1)
R21AT001628 (1)